Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Personalized chemotherapy profiling using cancer cell lines from selectable mice.

Kamiyama H, Rauenzahn S, Shim JS, Karikari CA, Feldmann G, Hua L, Kamiyama M, Schuler FW, Lin MT, Beaty RM, Karanam B, Liang H, Mullendore ME, Mo G, Hidalgo M, Jaffee E, Hruban RH, Jinnah HA, Roden RB, Jimeno A, Liu JO, Maitra A, Eshleman JR.

Clin Cancer Res. 2013 Mar 1;19(5):1139-46. doi: 10.1158/1078-0432.CCR-12-2127. Epub 2013 Jan 22.

2.

The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma.

Hillion J, Smail SS, Di Cello F, Belton A, Shah SN, Huso T, Schuldenfrei A, Nelson DM, Cope L, Campbell N, Karikari C, Aderinto A, Maitra A, Huso DL, Resar LM.

Pancreatology. 2012 Jul-Aug;12(4):372-9. doi: 10.1016/j.pan.2012.05.005. Epub 2012 May 29.

3.

A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C, Steenbergen C, Gabrielson KL, Maitra A, Maitra A.

Oncotarget. 2012 Jun;3(6):640-50.

4.

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.

Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):E252-9. doi: 10.1073/pnas.1114817109. Epub 2012 Jan 10.

5.

Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas.

Fendrich V, Oh E, Bang S, Karikari C, Ottenhof N, Bisht S, Lauth M, Brossart P, Katsanis N, Maitra A, Feldmann G.

Neoplasia. 2011 Oct;13(10):923-30.

6.

A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.

Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, Rudin CM, Maitra A.

Mol Cancer Ther. 2012 Jan;11(1):165-73. doi: 10.1158/1535-7163.MCT-11-0341. Epub 2011 Oct 25.

7.

SMURF1 amplification promotes invasiveness in pancreatic cancer.

Kwei KA, Shain AH, Bair R, Montgomery K, Karikari CA, van de Rijn M, Hidalgo M, Maitra A, Bashyam MD, Pollack JR.

PLoS One. 2011;6(8):e23924. doi: 10.1371/journal.pone.0023924. Epub 2011 Aug 22.

8.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.

Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD.

Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.

9.

Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts.

Zhang YA, Maitra A, Hsieh JT, Rudin CM, Peacock CD, Karikari C, Brekken RA, Stastny V, Gao B, Girard L, Wistuba I, Frenkel E, Minna JD, Gazdar AF.

Cancer Biol Ther. 2011 Oct 1;12(7):617-28. Epub 2011 Oct 1.

10.

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M.

Clin Cancer Res. 2011 Sep 1;17(17):5793-800. doi: 10.1158/1078-0432.CCR-11-0341. Epub 2011 Jul 8.

11.

Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice.

Pramanik D, Campbell NR, Karikari C, Chivukula R, Kent OA, Mendell JT, Maitra A.

Mol Cancer Ther. 2011 Aug;10(8):1470-80. doi: 10.1158/1535-7163.MCT-11-0152. Epub 2011 May 27.

12.

Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer.

Feldmann G, Karikari C, dal Molin M, Duringer S, Volkmann P, Bartsch DK, Bisht S, Koorstra JB, Brossart P, Maitra A, Fendrich V.

Cancer Biol Ther. 2011 Jun 1;11(11):959-68. Epub 2011 Jun 1.

13.

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC, Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A.

Cancer Biol Ther. 2010 Nov 15;10(10):1009-18. doi: 10.4161/cbt.10.10.13248. Epub 2010 Nov 15.

14.

Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.

Bisht S, Mizuma M, Feldmann G, Ottenhof NA, Hong SM, Pramanik D, Chenna V, Karikari C, Sharma R, Goggins MG, Rudek MA, Ravi R, Maitra A, Maitra A.

Mol Cancer Ther. 2010 Aug;9(8):2255-64. doi: 10.1158/1535-7163.MCT-10-0172. Epub 2010 Jul 20.

15.

Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma.

Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A.

Pancreatology. 2010;10(1):66-73. doi: 10.1159/000231984. Epub 2010 Mar 20.

16.

In vivo and in vitro propagation of intraductal papillary mucinous neoplasms.

Kamiyama H, Kamiyama M, Hong SM, Karikari CA, Lin MT, Borges MW, Griffith M, Young A, Norris-Kirby A, Lubek C, Mizuma M, Feldmann G, Shi C, Liang H, Goggins MG, Maitra A, Hruban RH, Eshleman JR.

Lab Invest. 2010 May;90(5):665-73. doi: 10.1038/labinvest.2010.51. Epub 2010 Mar 15.

17.

Cell cycle inhibition and apoptosis induced by curcumin in Ewing sarcoma cell line SK-NEP-1.

Singh M, Pandey A, Karikari CA, Singh G, Rakheja D.

Med Oncol. 2010 Dec;27(4):1096-101. doi: 10.1007/s12032-009-9341-6. Epub 2009 Oct 27.

PMID:
19859844
18.

Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.

Shi C, Chandrasekaran A, Thuluvath PJ, Karikari C, Argani P, Goggins M, Maitra A, Eshleman JR.

J Mol Diagn. 2009 Nov;11(6):583-9. doi: 10.2353/jmoldx.2009.090061. Epub 2009 Oct 8.

19.

Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer.

Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, Goggins MG, Mendell JT, Maitra A.

Pancreatology. 2009;9(3):293-301. doi: 10.1159/000186051. Epub 2009 Apr 29.

20.

The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.

Koorstra JB, Karikari CA, Feldmann G, Bisht S, Rojas PL, Offerhaus GJ, Alvarez H, Maitra A.

Cancer Biol Ther. 2009 Apr;8(7):618-26. Epub 2009 Apr 22.

21.

The Ape-1/Ref-1 redox antagonist E3330 inhibits the growth of tumor endothelium and endothelial progenitor cells: therapeutic implications in tumor angiogenesis.

Zou GM, Karikari C, Kabe Y, Handa H, Anders RA, Maitra A.

J Cell Physiol. 2009 Apr;219(1):209-18. doi: 10.1002/jcp.21666.

PMID:
19097035
22.

In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities.

Bisht S, Feldmann G, Koorstra JB, Mullendore M, Alvarez H, Karikari C, Rudek MA, Lee CK, Maitra A, Maitra A.

Mol Cancer Ther. 2008 Dec;7(12):3878-88. doi: 10.1158/1535-7163.MCT-08-0476.

23.

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, Koorstra JB, Habbe N, Karikari C, Mullendore M, Gabrielson KL, Sharma R, Matsui W, Maitra A.

Mol Cancer Ther. 2008 Sep;7(9):2725-35. doi: 10.1158/1535-7163.MCT-08-0573.

24.

Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer.

Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH, Montgomery K, Giacomini CP, Choi YL, Chatterjee S, Karikari CA, Salari K, Wang P, Hernandez-Boussard T, Swarnalata G, van de Rijn M, Maitra A, Pollack JR.

PLoS Genet. 2008 May 23;4(5):e1000081. doi: 10.1371/journal.pgen.1000081.

25.

Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer.

Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, Ouellette MM, Yu W, Maitra A.

Gut. 2008 Oct;57(10):1420-30. doi: 10.1136/gut.2007.148189. Epub 2008 May 30.

26.

Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery.

Tan AC, Fan JB, Karikari C, Bibikova M, Garcia EW, Zhou L, Barker D, Serre D, Feldmann G, Hruban RH, Klein AP, Goggins M, Couch FJ, Hudson TJ, Winslow RL, Maitra A, Chakravarti A.

Cancer Biol Ther. 2008 Jan;7(1):135-44. Epub 2007 Oct 19.

27.

Mitochondrial DNA mutations in pancreatic cancer.

Kassauei K, Habbe N, Mullendore ME, Karikari CA, Maitra A, Feldmann G.

Int J Gastrointest Cancer. 2006;37(2-3):57-64.

PMID:
17827523
28.

Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.

Karikari CA, Roy I, Tryggestad E, Feldmann G, Pinilla C, Welsh K, Reed JC, Armour EP, Wong J, Herman J, Rakheja D, Maitra A.

Mol Cancer Ther. 2007 Mar;6(3):957-66. Epub 2007 Mar 5.

29.

Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.

Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, Gabrielson KL, Matsui W, Maitra A.

Cancer Res. 2007 Mar 1;67(5):2187-96.

30.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

31.

Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.

Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, Chattopadhyay S, Hidalgo M, Maitra A.

Mol Cancer Ther. 2005 Dec;4(12):1860-6.

32.

Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A, Pollack JR.

Neoplasia. 2005 Jun;7(6):556-62.

33.

Lymphatic filariasis in Ghana: establishing the potential for an urban cycle of transmission.

Gbakima AA, Appawu MA, Dadzie S, Karikari C, Sackey SO, Baffoe-Wilmot A, Gyapong J, Scott AL.

Trop Med Int Health. 2005 Apr;10(4):387-92.

34.

Sex-specific development of cortical monoamine levels in mouse.

Connell S, Karikari C, Hohmann CF.

Brain Res Dev Brain Res. 2004 Jul 19;151(1-2):187-91.

PMID:
15246704

Supplemental Content

Loading ...
Support Center